Uterine Carcinosarcoma Clinical Trial
Official title:
A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
This phase II trial is studying how well thalidomide works in treating patients with carcinosarcoma of the uterus that has come back or that does not go to remission (decrease or disappear but may still be in the body) despite treatment. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
OBJECTIVES: Primary I. Determine the antitumor cytostatic activity of thalidomide, as
measured by the probability of progression-free survival (PFS) for at least 6 months, in
patients with recurrent or persistent uterine carcinosarcoma.
II. Determine the nature and degree of toxicity of this drug in these patients.
Secondary I. Determine the partial and complete response rates in patients treated with this
drug.
II. Determine the duration of PFS and overall survival of patients treated with this drug.
III. Determine the effect of this drug on initial performance status and histological grade
in these patients.
IV. Correlate serum and plasma biomarkers, including vascular endothelial growth factor and
basic fibroblast growth factor, with clinical outcome (i.e., PFS) in patients treated with
this drug.
OUTLINE: This is a multicenter study.
Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 28 days in
the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
annually thereafter.
PROJECTED ACCRUAL: A total of 19-51 patients will be accrued for this study within 3 years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01010126 -
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
|
Phase 2 | |
Completed |
NCT01168232 -
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
|
Phase 2 | |
Completed |
NCT00390234 -
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT00245102 -
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
|
Phase 2 | |
Recruiting |
NCT05902988 -
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05619913 -
EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
|
Phase 2 | |
Completed |
NCT00687687 -
Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma
|
Phase 2 | |
Completed |
NCT00114218 -
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
|
Phase 2 | |
Terminated |
NCT01367301 -
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer
|
N/A | |
Withdrawn |
NCT03902379 -
Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer
|
N/A | |
Completed |
NCT03694262 -
The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)
|
Phase 2 | |
Completed |
NCT01247571 -
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
|
Phase 2 | |
Terminated |
NCT01061606 -
Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus
|
Phase 2 | |
Completed |
NCT00075400 -
Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer
|
Phase 2 | |
Completed |
NCT00659360 -
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT00238121 -
Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
|
Phase 2 | |
Recruiting |
NCT05147558 -
A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
|
Phase 2 | |
Active, not recruiting |
NCT00954174 -
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
|
Phase 3 | |
Completed |
NCT00478426 -
Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05229601 -
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
|
Phase 1 |